Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
Ormerod
A D
AD
D000279:Administration, Cutaneous; D000818:Animals; D003879:Dermatologic Agents / Q000009:adverse effects*; D004195:Disease Models, Animal; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D009369:Neoplasms / Q000139:chemically induced*; D016559:Tacrolimus / Q000009:adverse effects* / Q000031:analogs & derivatives*
D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus